Gonadotropin-releasing hormone analog therapeutics

Claire L Newton, Claire Newton, Carmen Riekert, Robert P Millar
Minerva ginecologica · 2018 · vol. 70(5) , pp. 497–515 · doi:10.23736/s0026-4784.18.04316-2 · PMID:30264955 · W2897338025
review OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-14 ⓘ

GnRH analogs are effective treatments for hormone-dependent diseases by regulating the hypothalamic-pituitary-gonadal axis and are also utilized in assisted reproductive therapies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Dysregulation at any level of the hypothalamic-pituitary-gonadal (HPG) axis results in, or aggravates, a number of hormone-dependent diseases such as delayed or precocious puberty, infertility, prostatic and ovarian cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, endometriosis, uterine fibroids, lean body mass, as well as metabolism and cognitive impairment. As gonadotropin-releasing-hormone (GnRH) is an essential regulator of the HPG axis, agonist and antagonist analogs are efficacious in the treatment of these conditions. GnRH analogs also play an important role in assisted reproductive therapies. This review highlights the current and future therapeutic potential of GnRH analogs and upstream regulators of GnRH secretion.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Drug Design Gonadotropin-Releasing Hormone Hypothalamo-Hypophyseal System Animals Female Female Urogenital Diseases Female Urogenital Diseases Female Urogenital Diseases Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Hypothalamo-Hypophyseal System Male Male Urogenital Diseases Male Urogenital Diseases Male Urogenital Diseases Reproductive Techniques, Assisted

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (3)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:19:31.300640+00:00
License: CC0 · commercial use OK